NCT06767111

Brief Summary

The clinical study is a multi-center, retrospective, blinded, matched-pair, two-arm clinical study in which one test assessment and a control assessment of liquid-based cytology (LBC) pap tests are performed and compared to a reference. The control method is defined as the assessment of LBC pap tests performed by a cytotechnologist (CT) and/or cytopathologist (CP) using standard laboratory cervical cytology practices (i.e. a manual assessment) and following The Bethesda System for Reporting Cervical Cytology (TBS). The control method is referred to as the "standard method". The test method is referred to as the AI-assisted method. The AI-assisted method is defined as the assessment of the same LBC pap test as in the standard method, but with the Techcyte SureView Cervical Cytology System, which has pap tests being scanned on the Pramana SpectralHT Cubiq whole slide scanner, analyzed with the Techcyte Cervical Cytology Algorithm (TCCA) and presented on the Techcyte Viewer, using the Dell U3223QE Monitor for assessment by a CT/CP following the TBS. In addition, the time spent reviewing the samples with both methods will be measured such that the CT workload limit for AI-assisted assessment can be established. The LBC pap tests to be assessed in the clinical study must have been prepared with either ThinPrep® Pap Test (Hologic) or BD SurePath™ (Beckton, Dickinson and Company). The study aims to enroll for each preparation method an equal number of samples.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
4,596

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2024

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 6, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 9, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

September 4, 2025

Status Verified

September 1, 2025

Enrollment Period

1 year

First QC Date

January 6, 2025

Last Update Submit

September 2, 2025

Conditions

Keywords

in vitro diagnostic deviceIVDAIwhole slide scannerpap test slidepapcervical cytologydigital pathologydigital cytopathology

Outcome Measures

Primary Outcomes (1)

  • Sensitivity and specificity when comparing pap tests using the Techcyte SureView Cervical Cytology System

    The primary objective of the study is to show that the assessment of LBC pap tests using the Techcyte SureView Cervical Cytology System, i.e. the AI-assisted method, is non-inferior to current standard practice, i.e., the standard method, at the LSIL+ threshold used for cytologic diagnosis (specimen adequacy and descriptive diagnosis) as defined by The Bethesda System for Reporting Cervical Cytology.

    1 day

Interventions

Digital cervical cytology slide imaging system with artificial intelligence (AI) algorithm to be used for AI-assisted review

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Samples collected in the United States

You may qualify if:

  • Glass slides with cervical cytology specimens prepared with Hologic ThinPrep according to the pap test manufacturers Instructions for Use (IFU) using any of Hologic's processors (i.e. ThinPrep2000, ThinPrep 3000, ThinPrep 5000, ThinPrep Genesis). OR Glass slides with cervical cytology specimens prepared with BD SurePath according to the pap test manufacturers IFU using any of BD's processors (i.e. BD Totalys MultiProcessor, BD Totalys SlidePrep, BD PrepStain).
  • Slide has the original diagnosis available.
  • Slides that fit within the required sample size strata using the sample collection procedure.
  • Glass slides with QR code, barcodes, or plain text labels.
  • Glass slides with coverslips.
  • Slides that are 5 years old or less, except where rare specimens require it. Those specimens will have to be reviewed for degradation per the sample collection procedure.
  • Only one sample per patient and all are to be collected, processed and scanned.

You may not qualify if:

  • Broken or cracked slides.
  • Slides with air bubbles or scratched, cracked or broken/missing cover slips.
  • Slides with markings (e.g., handwritten pen marking) that cannot be removed according to standard laboratory procedures.
  • Degraded slides (ex: slides whose stains have lost color or specimens that are not intact).
  • Glass slides with cervical cytology specimens prepared with methods other than Hologic ThinPrep or BD SurePath.
  • Glass slides with specimens other than cervical cytology specimens.
  • Slides from the same patient.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Techcyte

Orem, Utah, 84057, United States

Location

Related Publications (1)

  • Nayar R, Wilbur DC. (eds), The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes. 3rd ed. Cham, Switzerland: Springer: 2015.

    BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

Pap test slides prepared using the ThinPrep and SurePath methods. These slides are prepared prior to the study.

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 6, 2025

First Posted

January 9, 2025

Study Start

December 1, 2024

Primary Completion

December 1, 2025

Study Completion

December 1, 2025

Last Updated

September 4, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations